title: Is there a sweet spot for Nrf2 activation in the treatment of diabetic kidney disease?
authors.affiliation: Division of Nephrology, Department of Medicine, Stanford University, Palo Alto, CA.
authors.forename: Evan T
authors.initials: ET
authors.lastname: Hall
authors.affiliation: Division of Nephrology, Department of Medicine, Stanford University, Palo Alto, CA vbhalla@stanford.edu.
authors.forename: Vivek
authors.initials: V
authors.lastname: Bhalla
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000517:prevention & control*; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D008297:Male; D009828:Oleanolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: C547749:dh404 compound; D009828:Oleanolic Acid